Cite
HARVARD Citation
Sharma, S. et al. (2022). Bioequivalence and Relative Bioavailability Studies to Assess a New Acalabrutinib Formulation That Enables Coadministration With Proton‐Pump Inhibitors. Clinical pharmacology in drug development. 11 (11), pp. 1294-1307. [Online].